|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The gross appearance of the capsules as well as the presence, extent and depth of tumor cells on the luminal side and number of sections involved by lymphoma were determined by review of routine stains and CD30 immunohistochemistry.
|
31383966 |
2020 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
While our understanding of the biology of CD30 in lymphoma continues to evolve, our need to detect and measure its expression at the protein level remains critically important for diagnosis and patient care.
|
31567279 |
2020 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Galectin-1 (Gal-1) has been associated with adverse prognosis in several cancers including lymphoma entities with CD30 expression.
|
31834627 |
2020 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas.
|
31838747 |
2020 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Pseudocarcinomatous (pseudoepitheliomatous) hyperplasia represents reactive epidermal change mimicking squamous cell carcinoma (SCC), owing to a variety of inflammatory and neoplastic phenomena, including deep fungal infections, CD30-positive lymphomas, and others.
|
30734344 |
2019 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The authors present four cases characterized by cutaneous infiltrates of cytotoxic CD30 negative CD4 positive T cells in the skin; three cases were forms of malignant lymphoma other than mycosis fungoides and one case was a reactive lymphomatoid photodermatosis associated with underlying collagen vascular disease.
|
30572149 |
2019 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Several ongoing and upcoming clinical trials of CD30-directed CAR-T cells are expected to further enhance this approach to treat patients with relapsed and refractory CD30+ lymphomas.
|
30841880 |
2019 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Anaplastic large cell lymphoma (ALCL) and classical Hodgkin lymphoma (cHL) are lymphomas that contain CD30-expressing tumor cells and have numerous pathological similarities.
|
31581676 |
2019 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CD30 is a member of the tumor necrosis factor family of cell surface receptors normally expressed in lymphocytes, as well as some lymphomas, but has been described in other malignancies.
|
31393373 |
2019 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, the tumor necrosis factor receptor superfamily cluster of differentiation 30 (CD30) has been thought to be implicated in malignant cells in organs affected by Hodgikin lymphoma or in a prognostic marker of diffuse large B cell lymphoma.
|
31335688 |
2019 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Purpose Brentuximab vedotin (BV) is an anti-CD30 antibody-drug conjugate used in the treatment of several types of lymphomas.
|
30993587 |
2019 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CD8<sup>+</sup> LyP with lack of expression of CD30 may have distinct histopathologic features that resemble mycosis fungoides and LyP type B. Clinically, they are indistinguishable from their CD30<sup>+</sup> counterparts, signifying the importance of clinical correlation to avoid the erroneous diagnosis of lymphoma.
|
30520526 |
2019 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Anti-CD30 antibody-based therapy, including brentuximab vedotin (BV), has been shown to target malignant lymphomas with CD30 expression.
|
29052238 |
2018 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
CD30 immunohistochemistry (IHC) in malignant lymphoma is used for selection of patients in clinical trials using brentuximab vedotin, an antibody drug-conjugate targeting the CD30 molecule.
|
29758590 |
2018 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In this review, we focus on the impact of deregulated expression of AP-1 TFs in CD30-positive lymphomas including Classical Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma.
|
29597249 |
2018 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Classical Hodgkin Lymphoma (cHL) is primarily a B cell lymphoid neoplasm and a member of the CD30-positive lymphomas. cHL and the other CD30-positive lymphomas are characterized by the elevated expression and/or constitutive activation of the activator protein-1 (AP-1) family transcription factors, c-Jun and JunB; however, the specific roles they play in the pathobiology of cHL are unclear.
|
30375407 |
2018 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Their specific features and relationship to CD30-expressing Hodgkin and Reed/Sternberg (HRS) cells of Hodgkin lymphoma are unclear but highly relevant, because numerous patients with lymphoma are currently treated with an anti-CD30 immunotoxin.
|
29889102 |
2018 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
It is approved for the treatment of certain R/R CD30+ lymphomas.
|
30362019 |
2018 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, anti-CD30-LDM shows attractive tumor-targeting capability and antitumor efficacy both in vitro and in vivo and could be a promising candidate for the treatment of CD30<sup>+</sup> lymphomas.
|
29316337 |
2018 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Our experience suggests that brentuximab use pre-allogeneic SCT is not associated with any significant post-transplant toxicity, and is associated with a rapid response in a majority of patients with relapsed/refractory CD30 positive lymphomas.
|
28247950 |
2017 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Whereas the expression of CD30 in cutaneous CD30+ T-LPD stands for a favourable prognosis, its expression in other cutaneous and systemic lymphomas has a divergent impact.
|
27993440 |
2017 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CD30 expression in extranodal natural killer/T-cell lymphoma, nasal type among 622 cases of mature T-cell and natural killer-cell lymphoma at a single institution in South China.
|
28486951 |
2017 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Brentuximab vedotin is an antibody-conjugated chemotherapy targeting CD30 indicated in treatment of several lymphomas.
|
28638848 |
2017 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Inclusion criteria: all retrospective reviews and case reports citing CD30 positivity or negativity in non-lymphomatous malignancies in which data were presented based on location.
|
28427526 |
2017 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expert commentary: Recognition of CD30 expression in lymphoma has led to the development of important therapeutic options.
|
27927047 |
2017 |